Clinical responses to dasatinib according to mutation type. The percentage of patients with imatinib-resistant or imatinib-intolerant CML achieving a complete or minor hematologic (CHR/mHR; light blue bars) or major cytogenetic response (dark blue bars) is analyzed according to dasatinib sensitivity (using classifications listed in Figure 1). The 4 panels represent patients with (A) no Bcr-Abl mutation or (B-D) baseline Bcr-Abl mutations predicted to confer (B) dasatinib sensitivity, (C) intermediate dasatinib sensitivity, or (D) dasatinib insensitivity. The results were compiled from four studies and are segregated by disease stage (M-BC, myeloid blast crisis; L-BC, lymphoid blast crisis).^11,38,–40  The number of patients (no.) in each category is indicated. Note that this analysis does not take the duration of response into account. Dasatinib response data is categorized by mutation type: native Bcr-Abl, sensitive 244M>V, 250G>E, 253Y>H, 311F>L, 351M>T, 359F>V, 379V>I, 387L>M, 396H>R, intermediate sensitivity (252Q>H, 255E>K, 255E>V, 317F>L), or 315T>I.